New T cell therapies for childhood cancers
Official title: NGTC - UCL
Funded at University College London · NIH-10631014 · Data updated 2026-11-12
This study is working on creating special treatments using T cells to help kids with tough-to-treat solid cancers, like certain types of sarcomas and brain tumors, by making these immune cells better at finding and fighting cancer cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University College London NIH-funded |
| Lab location | 1 site (London, United Kingdom) |
| Project start | June 24, 2022 |
| Project end | May 31, 2026 |
| Funding year | 2022 |
| Award (this year) | $2,095,142 |
| NIH project number | 1OT2CA278730-01 |
| Project ID | NIH-10631014 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with solid tumors, particularly sarcomas and brain tumors, who have not responded to existing therapies.
✕Less likely to help
Patients with hematologic malignancies or those whose tumors do not fall within the targeted categories may not benefit from this research.
What this research studies
This research focuses on developing advanced T cell therapies specifically designed for treating childhood solid cancers, which are often resistant to current treatments. The approach involves engineering T cells to target and attack cancer cells more effectively, overcoming challenges such as tumor heterogeneity and a hostile tumor microenvironment. By studying primary tumors, the research aims to identify new targets for therapy and improve T cell function in these difficult-to-treat cancers. The project is structured into interconnected work packages, initially targeting pediatric sarcomas and brain tumors.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for children suffering from solid tumors.
How similar studies have gone: Previous research in engineered T cell therapies for adult cancers has shown promising results, suggesting potential for success in pediatric applications as well.
Where this research is happening
-
University College London
London, United Kingdom Active
Researchers
- Principal investigator: Pule, Martin — University College London
- Study coordinator: Pule, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.